Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 3/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.46 |
| ▸ | SMYD2 | Q9NRG4 | 4/20 | 0.45 |
| ▸ | IKBKB | O14920 | 2/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | ATR | Q13535 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498295 | 0.84 | MTOR (0.62) | MTORSMG1IKBKBCA1CA2 | |
| SCHEMBL1633635 | 0.84 | ACHE (0.48) | BRAFSRCMTORSMG1IKBKB | |
| SCHEMBL1633418 | 0.84 | MAP4K4 (0.46) | MTORSMG1IKBKBMAP4K4FGFR2 | |
| SCHEMBL1632764 | 0.83 | BRD4 (0.51) | PTK2 | |
| SCHEMBL1632155 | 0.82 | IKBKB (0.46) | SRCMTORSMG1IKBKBMAP4K4 | |
| SCHEMBL1633149 | 0.81 | CA1 (0.48) | SRCMTORSMG1IKBKBFGFR2 | |
| SCHEMBL1633437 | 0.81 | JAK2 (0.54) | MTORSMG1IKBKBCA1CA2 | |
| SCHEMBL1632623 | 0.81 | MAPK10 (0.53) | SRCMTORSMG1IKBKBABL1 | |
| SCHEMBL1632981 | 0.81 | CA1 (0.47) | BRAFSRCMTORSMG1IKBKB | |
| SCHEMBL13498361 | 0.79 | JAK2 (0.49) | IKBKBPTK2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | BRAF 334/4885SRC 1131/4885MTOR 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.